Delivering on the Promise of Precision Medicine with Digital Measures in Neurology

Harnessing More Quantitative, Objective & Less Invasive Measures to Reduce Costs & Improve Neurology Patient Experience

2023 welcomed SV95C as the first ever digital endpoint qualified by a regulatory agency, which means that the floodgates have now opened to the potential of digital biomarkers to transform clinical development in neurology.

From the latest validated research on implementing speech, cognition, and motor tracking measures into clinical development, to navigating the regulatory and commercial landscape, the 3rd Digital Biomarkers & Clinical Measures for Neurology Summit is the ultimate platform to take your digital strategy to the next level.

This August, join 80+ senior industry leaders across digital health, medical affairs, clinical development, and regulatory this year from Biogen, DEEP Measures, Janssen, Alexion Pharmaceuticals, Eisai, Pfizer, Novo Nordisk, Novartis, Boehringer Ingelheim, Takeda, MTP, BMS, Alto Neurosciences, Michael J. Fox Foundation, Cerevel Therapeutics, Regeneron and many more…